Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis

Liver International

Volumn 35, Issue 2, 2015, Pages 582-590

  Yamada, Kazutoshi ^a   Mizukoshi, Eishiro ^a   Sunagozaka, Hajime ^a   Arai, Kuniaki ^a   Yamashita, Tatsuya ^a   Takeshita, Yumie ^a   Misu, Hirofumi ^a   Takamura, Toshinari ^a   Kitamura, Seiko ^b   Zen, Yoh ^b   Nakanuma, Yasuni ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Fatty acid metabolism; Insulin resistance; Palmitic acid; Toxic lipid

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCOSADIENOIC ACID; DOCOSAHEXAENOIC ACID; ERUCIC ACID; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; GONDOIC ACID; HEMOGLOBIN A1C; HEPTADECANOIC ACID; INSULIN; LAURIC ACID; LINOLEIC ACID; LINOLENIC ACID; MYRISTIC ACID; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCD1 PROTEIN; STEARIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYL COENZYME A DESATURASE; ACYLTRANSFERASE; FAS ANTIGEN; FAS PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; FATTY ACID ELONGASES; SCD1 PROTEIN, HUMAN; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; FATTY ACID ANALYSIS; FATTY ACID METABOLISM; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID COMPOSITION; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; GENE EXPRESSION PROFILING; LIVER; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY;

ACETYLTRANSFERASES; ANTIGENS, CD95; CHROMATOGRAPHY, GAS; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; GENE EXPRESSION PROFILING; HUMANS; INSULIN RESISTANCE; LIVER; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR GAMMA; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84921515371     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12685     Document Type: Article

References (26)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-61.
3. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
4. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-6.
5. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
6. Sanyal AJ, Unalp A; Investigators NC. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis REPLY. N Engl J Med 2010; 363: 1186-86.
7. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9.
8. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
10. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
11. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointest Liver Dis 2010; 19: 415-23.
12. Matsuzaka T, Shimano H, Yahagi N, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007; 13: 1193-202.
13. Li ZZ, Berk M, Mcintyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009; 284: 5637-44.
14. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
15. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
17. Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
18. Honda M, Yamashita T, Ueda T, et al. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006; 44: 1122-38.
19. Wang X, Cao YZ, Fu YW, Guo GF, Zhang XY. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis 2011; 10: 234.
20. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
21. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.
22. Shimomura L, Bashmakov Y, Ikemoto S, et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 13656-61.
23. Wang D, Wei YR, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006; 147: 943-51.
24. Listenberger LL, Han XL, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100: 3077-82.
25. Miyazaki M, Flowers MT, Sampath H, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007; 6: 484-96.
26. Matsuzaka T, Atsumi A, Matsumori R, et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 2012; 56: 2199-208.